Authors
Latest:
Commentary: It's Time to Repackage the Fight Against CigarettesTwenty million people in the United States have died from cigarette smoking since 1965.
Latest:
Why Practice Yoga?Yoga is a lifestyle that promotes health. Health, through yoga practice, encompasses physical, mental and spiritual well-being.
Latest:
Yoga for Cancer CareMind-body methods are increasingly being used in cancer treatment, as patients are supplementing standard care with integrative therapies.
Latest:
Persistence Paved the Path of Discovery for an Immunotherapy PioneerThomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.
Latest:
Dr. Newman on Health Disparities in Breast CancerLisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Dr. Villaruz on Updates From the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLCLiza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer.
Latest:
Clinical Ethics 101: Practical Ethical Principles for Oncology FellowsEducation in medical ethics is required in medical school and residency programs, yet there is so much variability in the timing and delivery of this education and many house staff report inadequacies and gaps in their ethical training.
Latest:
Dr. Gayle on Current Treatment Options in Breast Implant-Associated ALCLLloyd B. Gayle, MD, discusses current treatment options for patients who develop breast implant–associated anaplastic large cell lymphoma (ALCL).
Latest:
Dr. Damon on Optimal Treatment Regimens in AYA ALLLloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Dr. Clarke on Melanoma BiopsiesLoren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.
Latest:
Dr. Mell on Individualizing Treatment for Head and Neck CancerLoren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses individualizing treatments for patients with head and neck cancer.
Latest:
Dr. Loren Scott Michel on HPV-Associated Oropharyngeal CancerLoren Scott Michel, MD, Assistant Professor Medicine, Washington University, medical oncologist Siteman Cancer Center, discusses the link between human papillomavirus (HPV) and oropharyngeal cancers.
Latest:
Five-year Overall Survival (OS) and OS by Tumor Response Measures from the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)Dr. Lorenza Rimassa presents a five-year overall survival analysis from the Phase 3 HIMALAYA study, demonstrating sustained survival benefits of the STRIDE regimen versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).
Latest:
Dr. Erhunmwunsee on Factors of Disparity in Lung Cancer TreatmentLoretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.
Latest:
Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy WongOncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular LymphomaLoretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.
Latest:
Dr Leslie on the Utility of Axi-cel in High-Risk LBCLLori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.
Latest:
Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian CancerLori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.
Latest:
More Effort Needed to Understand Value Breadth of Molecular TestingAs the use of testing increases, so does the importance of understanding exactly what it can do for your patients and how to get the most out of the results.
Latest:
Lori Sakoda on Genetic Risk Variants for COPD and Lung CancerLori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.
Latest:
Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast CancerLori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.
Latest:
Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid CancerLori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.
Latest:
Interoperability Is the Key to a Patient-centric Transformation of the Healthcare SystemHealthcare data trapped in non-interoperable clinical systems leads to flawed processes, inefficient workflow, and less-than-optimal care.
Latest:
Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid LeukemiaOne promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.
Latest:
NSCLC Emerging as a Growing Problem Among Never-SmokersA substantial—and potentially growing—proportion of patients with non–small cell lung cancer are people who never, or only rarely, smoked.
